Skip to main content
Premium Trial:

Request an Annual Quote

Invitrogen Completes 95 Percent of BioReliance Merger

NEW YORK, Feb. 6 (GenomeWeb News) - Invitrogen announced today that its subsidiary, Baseball Acquisition, has accepted for purchase about 95 percent of the outstanding shares of BioReliance, a Rockville, Md.-based contract service organization.


Invitrogen announced in  December that it would acquire the company for $500 million. The announcement today said that Invitrogen would pay $48 per share for BioReliance's approximately 8.4 million shares.


The acquiring company said further that it intends to effect a short-term merger now that 95 percent of the shares are to be purchased. Once the merger has been entirely completed, BioReliance will become a wholly-owned subsidiary of Invitrogen.


The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.